St Jude outlines its cardiac rhythm strategy
This article was originally published in Clinica
Heart valve specialist St Jude Medical (US) has reported another quarter boosted by last year's Pacesetter purchase. Faced with frenzied acquisition activity by some competitors in its chosen field of cardiac rhythm management, St Jude is eager to stress its own progress and dispel any impression that it is slow to continue its diversification strategy.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.